Softcare (2698) H2 2025 earnings summary

Executive summary

• FY2025 revenue rose 24.9% YoY to US$567.4m, gross profit increased 27.1% to US$203.5m, and profit for the year grew 27.4% to US$121.2m.

• Main Board listing completed in November 2025; expanded local production and distribution supported growth across emerging markets.

Financial highlights

• Revenue was US$567.385m vs US$454.389m in 2024; gross profit was US$203.503m vs US$160.151m.

• Profit before tax reached US$144.669m vs US$113.081m; profit for the year was US$121.163m vs US$95.111m.

• Adjusted net profit, excluding listing expenses, FX gains/losses, share-based payments and related tax effects, was US$122.313m vs US$98.355m; adjusted margin held at 21.6%.

• Basic EPS was 23.0 US cents vs 19.0 cents; diluted EPS was 23.0 cents in 2025.

Outlook and guidance

• 2026 priorities include capacity upgrades, multi-brand development, refined channel management, product innovation and expansion in Latin America and other high-growth markets.

• Business scale and operational quality are expected to improve steadily, supported by emerging-market demand; no quantitative earnings guidance was stated.

• Continued focus on prudent financial, working-capital and cash-flow management, alongside flexible commercial and marketing strategies.